Molecular Pathogenesis and Therapeutic Approach of GM2 Gangliosidosis
Author:
- 1 February 2013
- journal article
- abstracts
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 133 (2) , 269-274
Abstract
Tay-Sachs and Sandhoff diseases (GM2 gangliosidoses) are autosomal recessive lysosomal storage diseases caused by gene mutations in HEXA and HEXB, each encoding human lysosomal β-hexosaminidase α-subunits and β-subunits, respectively. In Tay-Sachs disease, excessive accumulation of GM2 ganglioside (GM2), mainly in the central nervous system, is caused by a deficiency of the HexA isozyme (αβ heterodimer), resulting in progressive neurologic disorders. In Sandhoff disease, combined deficiencies of HexA and HexB (ββ homodimer) cause not only the accumulation of GM2 but also of oligosaccharides carrying terminal N-acetylhexosamine residues (GlcNAc-oligosaccharides), resulting in systemic manifestations including hepatosplenomegaly as well as neurologic symptoms. Hence there is little clinically effective treatment for these GM2 gangliosidoses. Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease. Experimental and therapeutic approaches, including recombinant enzyme replacement, have been performed using Sandhoff disease model mice, suggesting the future application of novel techniques to treat GM2 gangliosidoses (Hex deficiencies), including Sandhoff disease as well as Tay-Sachs disease. In this study, we isolated astrocytes and microglia from the neonatal brain of Sandhoff disease model mice and demonstrated abnormalities of glial cells. Moreover, we demonstrated the therapeutic effect of an intracerebroventricular administration of novel recombinant human HexA carrying a high content of M6P residue in Sandhoff disease model mice.Keywords
This publication has 25 references indexed in Scilit:
- Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic diseaseNature Medicine, 2007
- Effective gene therapy in an authentic model of Tay-Sachs-related diseasesProceedings of the National Academy of Sciences, 2006
- Possible role of autoantibodies in the pathophysiology of GM2 gangliosidosesJournal of Clinical Investigation, 2004
- Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantationBlood, 2001
- Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantationProceedings of the National Academy of Sciences, 2000
- Biochemical consequences of mutations causing the GM2 gangliosidosesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N -butyldeoxynojirimycinProceedings of the National Academy of Sciences, 1999
- Apoptotic Cell Death in Mouse Models of GM2 Gangliosidosis and Observations on Human Tay-Sachs and Sandhoff DiseasesHuman Molecular Genetics, 1997
- Mice lacking both subunits of lysosomal β–hexosaminidase display gangliosidosis and mucopolysaccharidosisNature Genetics, 1996
- Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolismNature Genetics, 1995